KRAS and neoplasm: Live tumor cells treated with anti-KRAS antibody also showed less intense cytoplasmic and less nuclear staining for SOX9, thus providing further evidence that SOX9, a cancer stem cell marker and potential driver in CRC (43, 48), is a downstream effector of KRAS signaling (Figures 3C–E).